<i>Erwinia</i> asparaginase after allergy to <i>E. coli</i> asparaginase in children with acute lymphoblastic leukemia

Abstract

Twice-weekly Erwinia asparaginase was well tolerated and achieved a therapeutically effective NSAA in most E. coli asparaginase-allergic patients. Development of E. coli allergy and subsequent treatment with twice-weekly Erwinia did not adversely impact event-free survival. Erwinia asparaginase should be considered for E. coli asparaginase-allergic patients.